CpG Adjuvants for Vaccine Development
CpG oligodeoxynucleotides are short single-stranded synthetic DNA molecules, containing unmethylated CpG dinucleotides in particular sequence contexts. It can lead to strong immunostimulatory effects by Toll-like receptor 9. It can induce high IFN-α production from plasmacytoid dendritic cells and has been tested as an adjuvant in animal models. Creative Biolabs offers a full range of custom CpG development services from design to use in vaccine development. We assist our clients in exploiting a wide array of novel technologies to produce safer and more efficacious vaccine adjuvants. We provide various screening parameters to meet our customers’ requirements. We have the short screening turnaround time and the competitive price with the best quality.
| CAT | Product Name | Product Overview | Type | Datasheet | Size | Price |
|---|---|---|---|---|---|---|
| VAdv-Ly0058 | ODN 2006-Type B (human, Biotin Conjugate) | ODN 2006-Type B, human TLR9 agonist, biotin conjugate, oligodeoxy nucleotide vaccine adjuvant. | CpG |  |
50 µg |
$958.00 |
| VAdv-Ly0059 | ODN D-SL01 | ODN D-SL01, a type B CpG ODN and a TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
200 µg |
$958.00 |
| VAdv-Ly0060 | ODN D-SL03 | ODN D-SL03, a type B CpG ODN and a TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
200 µg |
$958.00 |
| VAdv-Ly0063 | ODN M362-Type C (human/murine) | ODN M362-Type C, human/murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0064 | ODN 2395-Type C (human/murine) | ODN 2395-Type C, human/murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0065 | ODN 2336-Type A (human) | ODN 2336-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0066 | ODN 2216-Type A (human) | ODN 2216-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0067 | ODN 1668-Type B (murine) | ODN 1668-Type B, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0068 | ODN 2088-Type A (murine, Inhibitory TLR9 Antagonist) | ODN 2088-Type A, class A murine inhibitory ODNs, a potent inhibitor of TLR9-induced B cells and macrophages. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0069 | ODN 2006-Type B (human) | ODN 2006-Type B, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1463.00 |
| VAdv-Ly0070 | ODN 2006-Type B (human, Negative Control) | ODN 2006-Type B, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
5 mg |
$3760.00 |
| VAdv-Ly0071 | ODN 1668-Type B (murine, Negative Control) | ODN 1668-Type B, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0072 | ODN 2088-Type A (murine, Negative Control) | ODN 2088-Type A, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0073 | ODN 2007-Type B (bovine/porcine, Negative Control) | ODN 2007-Type B, bovine/porcine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0074 | ODN 1826-Type B (murine, Negative Control) | ODN 1826-Type B, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
5 mg |
$3760.00 |
| VAdv-Ly0075 | ODN 2216-Type A (human, Negative Control) | ODN 2216-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0076 | ODN 2395-Type C (human/murine, Negative Control) | ODN 2395-Type C, human/murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0077 | ODN 2336-Type A (human, Negative Control) | ODN 2336-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
| VAdv-Ly0078 | ODN M362-Type C (human/murine, Negative Control) | ODN M362-Type C, human/murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant. | CpG | |
1 mg |
$1446.00 |
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
